Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 24Vincristine 19Doxorubicin 17Radiotherapy 14Prednisone 13Methotrexate 13Cytarabine 13Rituximab 11Dexamethasone 11pegaspargase 10Filgrastim 10Etoposide 10Mercaptopurine 9Calcium Dobesilate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8azathiopurine 8auricularum 8Thioguanine 8Leucovorin 8Radiation 7Daunorubicin 7prednylidene 6deltacortene 6Asparaginase 6blinatumomab 5Prednisolone 5Peripheral Blood Stem Cell Transplantation 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Burkitt Lymphoma × tisagenlecleucel × Clear all
NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡